• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrroles Phenylpyrroles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrroles Substituted pyrroles Phenylpyrroles

Recent Advances in the Study of 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester (CAS: 163217-68-3)

The compound 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester (CAS: 163217-68-3) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development, particularly as an intermediate in the synthesis of statin-based therapeutics. Recent studies have focused on optimizing its synthetic pathways, understanding its biochemical interactions, and exploring its therapeutic potential. This research brief consolidates the latest findings and advancements related to this compound, providing a comprehensive overview for professionals in the field.

One of the key areas of investigation has been the optimization of synthetic routes for 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an improved synthetic protocol that enhances yield and purity while reducing the number of steps required. The researchers employed a novel catalytic system involving palladium-based catalysts, which significantly improved the efficiency of the benzyloxy group introduction. This advancement not only streamlines production but also reduces costs, making the compound more accessible for further research and development.

In addition to synthetic improvements, recent research has delved into the biochemical properties of 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester. A 2024 study in Bioorganic & Medicinal Chemistry Letters explored its interaction with HMG-CoA reductase, the target enzyme of statins. The findings suggested that the compound exhibits a unique binding affinity, potentially offering advantages over existing statin intermediates in terms of selectivity and potency. These insights could pave the way for the development of next-generation cholesterol-lowering agents with improved efficacy and reduced side effects.

Another significant development involves the exploration of 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester in combination therapies. Research conducted at the University of Cambridge (2023) investigated its synergistic effects with other lipid-modulating agents. The results indicated that the compound enhances the bioavailability of co-administered drugs, suggesting its potential as a pharmacokinetic booster in multi-drug regimens for cardiovascular diseases. This finding opens new avenues for combinatorial approaches in treating complex metabolic disorders.

Despite these promising advancements, challenges remain in the clinical translation of 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester. A recent review in Expert Opinion on Drug Discovery (2024) highlighted the need for more comprehensive toxicological studies and formulation optimization to address stability issues observed in preclinical models. Researchers are currently working on developing prodrug derivatives to improve the compound's metabolic stability and tissue distribution profiles.

In conclusion, the latest research on 4-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester (CAS: 163217-68-3) demonstrates significant progress in synthetic chemistry, biochemical understanding, and therapeutic potential. While challenges persist, the compound continues to show promise as a valuable intermediate in pharmaceutical development, particularly in the statin drug class. Future studies should focus on addressing the identified limitations and further exploring its applications in combination therapies and novel drug formulations.

• 581772-29-4(Atorvastatin Acetonide)
• 472967-95-6((3S,5S)-Atorvastatin Acetonide tert-Butyl Ester)
• 265989-39-7(2-Benzyloxy Atorvastatin Acetonide tert-Butyl Ester)
• 265989-36-4(4-Hydroxy Atorvastatin Acetonide tert-Butyl Ester)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)